Californian protein expert Rezo Therapeutics appoints new CEO

20 September 2023

Precision medicine specialist Rezo Therapeutics has appointed Nadir Mahmood as chief executive officer, replacing co-founder Nevan Krogan, who has held the role on an interim basis.

Dr Mahmood previously served as chief financial and business officer of US biotech Nkarta Therapeutics (Nasdaq: NKTX), and has extensive experience in the biopharmaceutical industry.

Before Nkarta, he led corporate development at Second Genome, where he was responsible for establishing strategy and partnerships across the company’s portfolio.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK